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Abstract  
Mannitol is a pharmaceutical excipient that is receiving increased popularity in solid 
dosage forms. The aim of this study was to provide comparative evaluation on the effect of 
mannitol concentration on the physicochemical, mechanical, and pharmaceutical properties of 
lyophilised mannitol. The results showed that the physicochemical, mechanical and 
pharmaceutical properties of lyophilised mannitol powders are strong functions of mannitol 
concentration. By decreasing mannitol concentration, the true density, bulk density, cohesivity, 
flowability, netcharge-to-mass ratio, and relative degree of crystallinity of LM were decreased, 
whereas the breakability, size distribution, and size homogeneity of lyophilised mannitol 
particles were increased. The mechanical properties of lyophilised mannitol tablets improved 
with decreasing mannitol concentration. The use of lyophilised mannitol has profoundly 
improved the dissolution rate of indomethacin from tablets in comparison to commercial 
mannitol. This improvement exhibited an increasing trend with decreasing mannitol 
concentration. In conclusion, mannitols lyophilised from lower concentrations are more desirable 
in tableting than mannitols from higher concentrations due to their better mechanical and 
dissolution properties. 
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1. Introduction 
Industrially, the ordinary method to produce pharmaceutical compounds in the micrometer 
size range is the ‘top-down’ size reduction by milling (Kaialy and Al Shafiee, 2015). However, 
despite its popularity, milling has several disadvantages (Parrott, 1990). For example, milling 
offers low opportunity to produce particles with controlled characteristics such as size, shape and 
surface properties (Snow et al., 1984). Jet-milled particles usually exhibit broad size distributions, 
irregular shapes (Rasenack and Müller, 2004), and high levels of electrostatic charges, resulting in 
increased interparticle cohesive forces and potentially leading to poor product performance 
(Brodka-Pfeiffer et al., 2003; Kaialy, 2016). Moreover, jet-milling is incompatible with thermally 
sensitive materials and may raise safety worries due to dust exposure during processing (Tong and 
Chow, 2006).  
Particle engineering techniques have been a subject to continuous improvement (Blagden 
et al., 2007). In contrast to jet-milling, particles with precisely engineered physical properties 
were, for instance, engineered using antisolvent crystallization (Kaialy et al., 2014, 2010), batch 
cooling crystallization (Kaialy et al., 2012), spray drying (Vehring, 2008), spray-freeze drying 
(Rogers et al., 2003), etc. Freeze-drying (lyophilisation) is a technical procedure that involves the 
removal of frozen water by sublimation. Lyophilised formulations commonly contain mannitol 
(C6H14O6) as a bulking agent to increase the drug volume and thus preventing the ‘blow-out’ 
phenomenon that may occur in the case of a solution having a content of solute less than 1%, w/v 
(Franks and Auffret, 2008). The relatively high melting temperature of the mannitol/ice eutectic 
mixture (~ −1.5 °C) promotes efficient drying and physical stability of lyophilised mannitol (LM) 
solids (Kim et al., 1998). Mannitol can be lyophilised to produce a crystalline product, with the 
only precaution to maintain the temperature below that of incipient melting (Barresi et al., 2009). 
Therefore, the lyophilisation of 10% w/w solutions resulted in crystalline and amorphous 
materials of mannitol and sucrose respectively (Franks and Aufrett, 2007). Although amorphous 
mannitol can serve as a stabiliser for the active pharmaceutical ingredient (API) (Izutsu et al., 
1994), the difficultly to maintain mannitol in the amorphous state during lyophilisation makes 
mannitol a poor choice as stabiliser (Pikal, 2002). However, the crystallisation of mannitol in 
frozen solutions during lyophilisation was inhibited by using phosphate buffer salts (Izutsu et al., 
1994), polyvinylpyrrolidone (Cavatur et al., 2002) and NaCl (Telang et al., 2003).  
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During lyophilisation, mannitol was shown to crystallise as three common stable 
anhydrous polymorphic forms (i.e. α, β and δ) (Bauer et al., 2000; Berman et al., 1968; Botez et 
al., 2003; Burger et al., 2000; Kim et al., 1968) or as mannitol hemihydrate (Cavatur and 
Suryanarayanan, 1998; Cavatur et al., 2002; De Beer et al., 2007; Nunes et al., 2004; Romero-
Torres et al., 2007; Yu et al., 1999). The polymorphic form of lyophilised mannitol was shown to 
have an effect in the stability of the lyophilised product during its storage (Cao et al., 2006; De 
Beer et al., 2009, 2007; Pisano et al., 2013). For example, the presence of hemihydrate mannitol 
in a lyophilised product could increase the rate of degradation, because hemihydrate mannitol is 
transformed during storage into anhydrous crystalline δ–mannitol by releasing its hydrate water 
within the amorphous phase containing the active pharmaceutical ingredient (Ahlneck and 
Zografi, 1990; Nunes et al., 2004). (Pisano et al., 2013) showed that a high content of mannitol in 
formulations containing mannitol and sucrose could better protect the enzyme molecules (acid 
phosphatase) from the dehydration stresses of lyophilization. Several studies showed the selection 
of the freezing method (Oddone et al., 2016) and the process conditions (Gan et al., 2004; Rene et 
al., 1993; Velardi and Barresi, 2008) as important parameters to be considered during cycle 
development. For example, (Kim et al., 1998) showed that a mixture of α– and β–mannitol was 
produced by slow freezing of 10% (w/v) mannitol, whereas fast freezing of 10% (w/v) and 5% 
(w/v) mannitol produced δ– and β–mannitol respectively. (Barresi et al., 2009) showed the 
temperature at which primary drying is carried out to affect the bulk density, rehydratability and 
residual moisture content of the lyophilised product. Higher rehydration rates were observed for 
products lyophilised at lower temperatures and lower initial concentrations. (Yu et al., 1999) 
showed the secondary drying conditions during freeze-drying as important parameters for the 
removal of the mannitol hemihydrate form. (Cannon and Trappler, 1999) showed slow cooling 
rates to promote the formation of α–mannitol. The use of surfactants, e.g. pluronic F68 (Hottot et 
al., 2008) and polysorbate (Haikala and Eerola, 1997), was shown to induce the formation of δ–
mannitol phase and inhibit mannitol crystallisation. 
Mannitol is an attractive pharmaceutical excipient that is becoming more and more 
popular in solid dosage forms (Ohrem et al., 2014). Mannitol shows the lowest hygroscopicity 
among the frequently used excipients as filler/binder and hence it can be utilized for moisture-
sensitive drugs. Furthermore, mannitol does not increase the levels of blood glucose to such an 
extent as lactose (Geil, 1996) and thus it is especially suitable for pharmaceutical formulations 
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that are used for diabetics (Zumbe et al., 2001). There is currently a strong driving force to use 
mannitol as an alternative excipient to lactose in pharmaceutical formulations (Eadala et al., 
2009). This is because lactose exhibits unpredictable physicochemical properties during 
pharmaceutical production processes such as milling (Steckel et al., 2006) and crystallization 
(Zeng et al., 2000). Although lactose monohydrate is the most commonly used filler in tablet 
manufacture, lactose particles are required to have small size distributions to show good 
compactibility, leading to poor flow properties (Vromans, 1987). Additionally, lactose has a 
degree of security as inert excipient due to its incompatibility with compounds that have primary 
amine moieties (e.g. budesonide and formoterol), since Maillard-type condensation reaction is 
likely to occur (Bharate et al., 2010). Furthermore, although the side effects of lactose intolerance 
will sometimes not be observed in a patient using the small amounts of lactose present in tablets, 
the NOCEBO-effect should not be ignored. Therefore, lactose-free formulations may be needed 
for lactose-intolerant patients (Picksak and Stichtenoth, 2009). Moreover, lactose is produced 
from bovine milk or with bovine-driven additives, thus it carries a potential risk of transmissible 
spongiform encephalopathy (EMA, 2002). Mannitol is valuable in the production of tablets due to 
its excellent mechanical compressing properties, physical and chemical stability (Ohrem et al., 
2014). Toxicity studies indicated that mannitol did not cause any considerable adverse effects 
(Lawson, 2000).  
This study contributes to the development of mannitol as a potential excipient of the first 
choice. The purpose was address the theory that the physicochemical, mechanical and 
pharmaceutical properties of lyophilised mannitol (LM) powders are strongly dependent on the 
concentration of mannitol solution subjected to lyophilisation as one variable.  
2. Materials and methods 
2.1. Materials 
Commercial mannitol (CM) was purchased from Fisher Scientific, UK. Indomethacin was 
purchased from Sigma-Aldrich, USA. Dissolution buffers were prepared according to the USP 
using potassium phosphate monobasic-white crystals (Fisher BioReagents, UK) and sodium 
hydroxide (Fisher Scientific, UK) for pH 7.2. 
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2.2. Preparation of lyophilised mannitols 
A series of mannitol solutions with concentrations of 15%, 10%, 5% and 1% (w/v) were prepared 
by separately dissolving 15 g, 10 g, 5 g and 1 g of mannitol in distilled water such that the final 
volume of each solution is 100 mL. Each solution was then filtered (<0.45 µm, cellulose filter 
paper), filled into 250 mL round-bottomed flasks (50 mL per flask), and consequently lyophilised 
using a similar protocol as follows. The flasks were kept in a freezer (−80 ºC) for 12 h. The flasks 
containing the frozen mannitol solutions were quickly placed on the shelves of a Christ Beta 1-8 
LD Freeze Dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) 
using manifolds. The primary drying was performed at a shelf temperature of −27 ºC, vacuum 
pressure of 0.518 mbar and a safety pressure of 0.700 mbar, whereas the final drying was 
performed at a shelf temperature of −35 ºC, vacuum pressure of 0.224 mbar and a safety pressure 
of 0.380 mbar. For safety reasons (especially for mannitols lyophilised from the lowest 
concentrations, i.e. 1% w/v), the primary drying was carried out at a fixed low temperature for all 
samples  in order to avoid collapse or ‘blow-out’ and to promote faster rehydratability of the LM 
products (Barresi et al., 2009; Franks and Auffret, 2008; Pikal-Cleland et al., 2000). The LMs 
were collected after 48 h. Fluffy LM powders were obtained with yields above 99% (w/w). The 
LM powders were sieved through a 0.50 mm sieve (Retsch® Gmbh Test Sieve, Germany), and 
stored in sealed glass vials in laboratory conditions (22 ºC, 50% RH) until used. The preparations 
were performed at least in triplicate using an identical protocol to ensure reproducibility. 
2.3. Helium pycnometry 
An electronic balance was used to measure the mass of a sample of each LM with an accuracy of 
10-4 g. The true volume of each mannitol sample (the volume apart from both open and closed 
pores) was determined using an Ultrapycnometer 1000 (Quantachrom, USA) under helium gas at 
an input pressure of 20 psi. A multi-run system was used with a standard deviation of 0.005% and 
an equilibrium time of 1 min. The true volume was calibrated with a calibration sphere 
(Quantachrome Corp.) and calculated from the change in pressure when a specific volume of 
helium is purged into the chamber. The mean of nine determinations was recorded for each 
sample. 
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2.4. Bulk properties 
An accurately weighed amount of each powder was gently poured into a 10–mL glass measuring 
cylinder using a glass funnel. The bulk volume was recorded and then the cylinder was tapped 
(Tapped Density Tester, Copley Scientific, UK) under laboratory conditions (22 °C, 50% = RH) 
for 500 taps (which was shown to produce the maximum reduction of powder bed for all 
samples). The volume was recorded after every 50 taps. Bulk density (or apparent density, Db), 
tap density (or drop density, Dt), porosity (Eq. 1) and Carr’s index (CI, Eq. 2) of each powder 
were calculated as follows. 
Porosity = (1-
𝑫𝒕
 𝑫𝒕𝒓𝒖𝒆
)  × 100    (1) 
CI = (
𝑫𝒕 – 𝑫𝒃
 𝑫𝒕
) × 100          (2). 
The packability was determined from the tapped density according to Kawakita and Ludde 
equation (Eq. 3) (Kawakita and Lüdde, 1971) as follows. 
n
C
 = 
1
ab
 +
 n
a
  (3), 
C = 
V0-Vn
V0
  (4), 
where n is the tap number, C donates the volume reduction (Eq. 4), and V0 and Vn are the powder 
bed volumes at the initial and nth tapped state respectively. The plot of n/C versus n is linear. 
Through the modified Kawakita and Ludde equation (Kawakita and Lüdde, 1971), the 
compactability (1/a) can be obtained from the slope a, and the cohesivity 1/b is obtained from the 
intercept 1/ab of the plot. The compactibility (1/a) defines the degree of volume reduction and the 
cohesivity (1/b) is a constant related to cohesion. Five different samples were analysed for each 
mannitol product. 
2.5. Laser diffraction 
Volume-weighted particle size analysis was conducted using a Sympatec (Clausthal–Zellerfeld, 
Germany) particle size analyser. To get primary particle size data (i.e. total dispersion), HELOS 
(H1730) & Cuvette (50 mL) system equipped with MS7 magnetically stirred cell and R5 lens 
(measuring range: from 0.5/4.5 µm to 875.0 µm) were used. The dispersion system was acetone 
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saturated with mannitol, sonicated for 30 min, stirred overnight and then filtered (< 0.45 µm, 
cellulose filter paper). A (100 to 200) mg sample of each product was dispersed in the dispersion 
system filled in a cuvette. A test reference (i.e. background measurement) was performed with the 
HELOS sensor using WINDOX 4.0 software followed by a standard measurement. The particle 
size measurements were carried out under stirring dispersion conditions (2000 rpm). Particle size 
at 10% (d10%), 50% (median diameter, d50%) and 90% (d90%) diameter based on volume 
distribution were calculated using the WINDOX 5 software (V 5.9.1.0). The optimal 
concentration (c.opt) ranged between 15 and 50% and the timebase was 1 ms. The width of the 
distribution relative to d50% was measured by calculating the span of the volume distribution (Eq. 
5). 
Span = 
d90%-d10%
d50%
   (5). 
Ten samples were measured for each mannitol product.  
For each sample, 20 sonications were applied consequently and the particle size data were 
recorded immediately to establish the influence of sonication time on the size of LM particles. 
Each sonication was for 10 s and the time between sonication and another was 1 min (the total 
effective sonication time applied for each sample was 200 s). To observe the relaxation of the 
effects of sonication on LM particles, the particle size of each sonicated (200 s) LM sample was 
monitored after 1 min, 15 min, 1 h and 3 h at the end of sonication. The particle size data were 
analysed by the following method to extract a ‘relative degree of breakage’ (RDB) parameter as 
follows (Eq. 6).  
RDB = 
d50%t=0
d50%t=200
   (6). 
The particle size (expressed as the median diameter) at each ultrasonication time (d50%t=0) was 
expressed as a proportion to the smallest achievable particle size (d50%t=200). The RDB was thus 
as a measure of the relative degree of particle breakage at any particular time. The RDB data were 
empirically modelled using the modified Michaelis–Menten equation linearised using the Hanes–
Woolf method (Eq. 7). 
t
RDB
 = 
1
EB
. t +
EB50%
EB
   (7), 
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where EB is the ‘ease of breakage’ which represents the maximum RDB calculated using the 
slope of the fitted regression line (SM–1). The EB50% represents the 50% RDB calculated from 
the intercept and slope of the regression line. 
2.6. Scanning electron microscopy 
A representative specimen of each LM sample was gently mounted on an aluminium stub covered 
with carbon. To increase the electric conductivity on the surface of the samples, a sputter coater 
(Edwards S 150B Sputter Coater, Edwards High Vacuum, West Sussex, UK) was used to coat the 
samples with chromium (12 nm layer thickness) in an argon atmosphere before observation. 
Electron micrographs of LM samples were obtained using a scanning electron microscope (SEM, 
HITACHI SU 8030, Japan) operating at an acceleration voltage of 1 kV and probe current of 10 
μA. Various magnifications (×130, ×500 and ×1500) were used to analyse the size, shape and 
surface texture of different LMs. 
2.7. Electrostatic charging 
The electrostatic charging properties of powders were analysed using a recent novel approach 
developed in the Wolfson Centre (University of Greenwich, UK) as described in (Hussain et al., 
2013). The experimental apparatus used to investigate the electrostatic charging of powders 
consists of a single non-contact electrostatic inductive sensor (i.e. a probe), a charge amplifier 
unit, a national instrument data acquisition equipment, and a personal computer for data recording 
and processing. This method allows the detection and measurement of charge distribution on the 
charge sign basis in a population of particles (Hussain et al., 2016). A sample of each powder was 
fed in the cylindrical sensor with the help of a vibratory feeder and conveyed toward the sensor by 
gravity in a vertical direction. Special care was taken by considering the adhesion properties of the 
particles with the wall of the sensor. After each experiment, the inner tube was replaced to remove 
any deposits, impurities or surface charge that may have been present on the surface from a 
previous test. A fresh sample was used for each test experiment. Each sample was analysed six 
times in a temperature and humidity controlled laboratory (22 °C, RH = 50%). The positive 
charge is the sum of all positive charges whereas the negative charge is the sum of all negative 
charges. The netcharge is the sum of positive and negative charges. The charge-to-mass ratio 
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(CMR) was defined as the charge (negative charge for N–CMR, positive charge for P–CMR and 
netcharge for net–CMR) per unit mass, in nC/g. 
2.8. Differential scanning calorimetry  
A differential scanning calorimeter (DSC822e, Mettler Toledo, Linseis, Germany) was conducted 
to characterise the solid-state of LMs. An accurately weighed sample of each LM product was 
placed in crimped aluminium 40–µL pans, and then heated from 25 °C to 200 ºC at a heating 
ramp rate of 30 ºC/min under a nitrogen gas atmosphere (50 L/min). An empty aluminium pan 
was used as the reference. Temperature and enthalpy readings were calibrated using pure indium 
heated at 30 ºC/min. The transition areas were automatically normalized for the weight of each 
sample using the STARe SW 11.00 software (Mettler, Switzerland). The % relative degree of 
crystallinity (RDCDSC) of each LM product was estimated from the ratio of the endothermic 
enthalpy of LM melting (∆Hs) to the calorimetric enthalpy of the melt of the reference crystalline 
mannitol (D-Mannitol, Fisher Scientific, UK) (∆H0) (Eq. 8).  
RDCDSC = 100 × (
∆Hs
∆Ho
) (8). 
Four different samples were analysed for each mannitol product. 
2.9. Fourier transform infrared spectroscopy  
To investigate whether mannitol was chemically altered during the freeze-drying process, the 
molecular structure of all LMs was analysed using an Alpha Platinum−ATR FT−IR spectrometer 
(BRUKER, USA). A few milligrams of each powder were placed into the middle of the sample 
stage, and then compressed by twisting the top of the arm of sample stage. The samples were 
scanned between 650 cm-1 and 4,000 cm-1 with a 1 cm-1 resolution. The spectrum produced for 
each sample was a consequence of averaging 15 scans. 
2.10. Powder X–ray diffraction 
Powder X–ray diffraction (PXRD) structural patterns of mannitols were collected using a 
Panalytical Empyrean diffractometer (PANanalyical, Almelo, The Netherlands) powder 
diffractometer with Cu Kα radiation (1.54056 Å) operated at laboratory conditions (22 ºC, RH = 
50%). Each sample was placed in a sample holder, surface-smoothed with a glass slide, and 
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scanned between 5º and 40º in 2Ɵ with a step-by-step increase of 0.01º 2Ɵ/1 s. The sample stage 
was spun at 30 rpm. The instrument was calibrated using a silicon standard. 
The identification of the different polymorphs of mannitol was achieved from the 2θ peaks at the 
following angle positions: α–polymorph at 13.6° and 17.2°, β–polymorph at 14.6° and 23.4°, and 
δ–polymorph at 9.7° (Walter-Levy, 1968). Quantitative analysis of mannitol crystal form (% α–, 
% β– and % δ–mannitol) was performed by Rietveld refinement using Topas v4 (Bruker) software 
package. Cif structural models of mannitol polymorphs were obtained from the Cambridge 
Structural Database, refined within Topas on pure mannitol samples, and then converted to ‘.str’ 
files. The area under the ‘crystalline peaks’ was measured for each PXRD diffractogram and used 
as a reference for the determination of relative degree of crystallinity. Assuming that the areas are 
proportional to the scattering intensities, the percent relative degree of crystallinity (RDCPXRD) 
(Eq. 9) was estimated from the integrated relative intensities (I) of all ‘crystalline peaks’ and the 
amorphous region under the diffraction curve. 
RDCPXRD = 100 × 
Icrystalline
Icrystalline + Iamorphous
   (9). 
The input to the intensity from the amorphous region (Iamorphous) was identified by accurately 
correcting the curvature of the background curve. The input to the intensity from the crystalline 
region (Icrystalline) was attained after deducting the background curve from the PXRD pattern. The 
reproducibility of the PXRD patterns was checked by performing four measurements of four 
different samples of each mannitol product. 
2.11. Karl Fischer titration 
The (residual) moisture content of LMs was determined by the Karl-Fisher method (Metter 
Toledo, C20 Coulometric KF Titrator, Switzerland). The Fischer reagent solution was Hydranal® 
Coulomat AF (Sigma-Aldrich, USA). Following the calibration of the instrument, samples were 
rapidly added into the titrator vessel at the laboratory temperature (22 ºC). The titration of each 
sample was repeated three times.  
2.12. Preparation of tablets 
Compression of mannitol powders was carried out using a single punch Specac press KBR 
25.011 (Gemini BV, The Netherlands), fitted with 6 mm diameter flat–faced punches to produce 
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round tablets with a target weight of (100 ± 0.5) mg. Before compression, the compaction surfaces 
were lubricated with 1% (w/v) magnesium stearate (Acrõs Organics, New Jersey, USA) in acetone 
(Fisher Scientific, UK) to reduce the friction between the die and the tablet, and to prevent the 
produced tablets from sticking to the die walls and punch faces. Tablets were compressed at 
increasing compression pressures of 173, 346, 520, 693, 861 and 1040 MPa under load for 20 s 
dwell time. Tablet diameter and thickness were measured using a digital micrometer (Fisher 
Scientific, UK) immediately after ejection and 24 h after ejection to allow for elastic recovery and 
possible hardening of tablets. Tablets were stored in screw-capped glass vials (22 ºC, 50% RH). 
The results were the mean and standard deviation of five determinations. 
2.13. Crushing strength and capping tendency 
The crushing strength was determined from the force required to fracture the tablet by 
diametral compression on a motorised Vankel Tablet Hardness Tester (Model Bench Saver VK 
200, USA). The tensile strength (TS) (Eq. 10) of each compact was calculated using the following 
equation (Fell and Newton, 1970). 
TS = 
2F
πDt
  (10), 
in which D and t are the diameter and thickness (mm) of the compact respectively, and F 
is the force exerted to fracture the compact. Tablets were assessed visually for capping by 
observation of the produced tablets for horizontal striations. Tests were carried out 24 h after 
ejection. Five tablets were selected for crushing strength measurements. 
2.14. Preparation of mannitol–indomethacin formulations 
LM powders were formulated with indomethacin, a model poorly water-soluble drug, to 
evaluate the in vitro dissolution performance of tablets containing LM in comparison to CM. Each 
tablet contained a mixture of 75 mg mannitol and 25 mg indomethacin (excipient to drug ratio of 
3:1, w:w). The blending was performed in a cylindrical aluminium container (6.5 cm × 8 cm) 
using a Turbula® mixer (Maschinenfabrik, Basel, Switzerland) at a constant speed of 90 rpm for 
30 min in laboratory conditions (22 ºC, RH = 50%) for the preparation of all formulations under a 
similar protocol. Once prepared, all formulations were stored in tightly sealed glass vials for 7 
days (22 ºC, RH = 50%) before further operations to allow any possible charge relaxation to 
occur. 
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2.15. In vitro dissolution 
A USP dissolution apparatus no. 1 (Erweka DT700, Germany) was used to monitor the in 
vitro dissolution profiles of indomethacin from tablets containing different mannitols compressed 
at a fixed pressure (173 MPa). The amounts of dissolved drug were analysed using a 
spectrophotometer (UV–160, Shimadzu, Japan) at 318 nm. The dissolution medium (900 mL of 
phosphate buffer of pH 7.2) was equilibrated to (37 ± 0.5) ºC at 50 rpm using the rotating paddle 
method. From the dissolution flasks, samples were withdrawn at predetermined time intervals (2, 
4, 6, 8, 10, 15, 20, 25, 30, 35, 40, 50, 55, 60, 70, 80, 90, 100, 110 and 120 min). Three tablets 
were tested for each formulation. 
2.16. Dissolution parameters 
The dissolution efficiency (%DE, Eq. 11) was calculated from the area under the 
dissolution curve up to the time, t, expressed as the percentage of the area of the rectangle (Khan, 
1975). 
DEt = 
∫ y × 
t
0
dt
y100 × t
 × 100      (11), 
where y is the percent amount of the drug dissolved at time t. The mean dissolution time (MDT, 
Eq. 12) was calculated as the mean time for the drug to dissolve under in vitro dissolution 
conditions. 
MDT = 
∑ tj
n
j=1 ∆Mj
∑ ∆Mj
n
j=1
   (12), 
where j is the sample number, n is the number of dissolution sample times, tj is the 
midpoint of the jth time period (calculated from [t+(t-1)/2]) and ∆Mj is the additional amount of 
the drug dissolved between tj and t-1. The mean dissolution rate (MDR, Eq. 13) was calculated as 
the percent release of the drug every min using the following equation. 
MDR = 
∑ ∆Mj
n
j=1 /∆t
n
    (13),  
where n is the number of dissolution times, ∆t is the time at the midpoint between t and 
t−1 (calculated from [t + t−1)/2]) and ∆Mj is the additional amount of the drug dissolved between 
tj and t−1. Additionally, as independent metrics, the mean percentage of the drug dissolved in the 
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first 4 min (Q4min), 10 min (Q10min), 30 min (Q30min) and 50 min (Q50min) were used to characterize 
the dissolution rate from various tablets. 
2.17. Statistical analysis 
One way analysis of variance (ANOVA) test was applied to compare the mean results for 
all data in this study considering P values less than 0.05 an as indicative of a significant 
difference. Data groups that showed a significant difference (ANOVA, P <0.05) were further 
subjected to the Tukey’s post hoc test to identify which specific groups differed. The data are 
generally expressed as the mean ± standard deviation (SD). 
 
3. Results and discussion 
3.1. Density, porosity and cohesivity  
Following freeze-drying, the true density of mannitol particles decreased (P <0.05) from 
(1.50 ± 0.02) g/cm3 (CM) to the range between (1.19 ± 0.04) g/cm3 and (1.45 ± 0.02) g/cm3 (Table 
1), indicating that LM particles do not have the same crystalline structure as CM. In comparison 
to CM, LMs demonstrated considerably lower bulk densities, lower tap densities, higher 
porosities, lower compactibilities and higher cohesivities (Table 1), indicating a lower number of 
average contact points between LM particles. This is because LMs exhibited loosely packed 
powder systems, leading to reduced interparticle contact areas and thus reduced interparticle 
forces as compared to CM. By comparing LMs only, regression analysis showed that by 
decreasing mannitol concentration, there was a decrease in the true density, bulk density (Db, 
linear, r2 = 0.9896), tap density (Dt, linear, r
2 = 0.99), along with an increase in porosity (linear, r2 
= 0.992) and cohesivity (1/b, r2 = 0.8139) of LM products (Table 1). This is because the bulk 
density of the LM product depends on the freezing step. Freezing determine the dimension and the 
shape of the ice crystals that form the structure of the frozen LM product (Kochs et al., 1993; 
Nakagawa et al., 2006; Searles et al., 2001). Regardless of the concentration of mannitol solution, 
the LM powders were solids occupying approximately the volume of the former solution. 
Therefore, the volume of 1 g of mannitol increased from (1.8 ± 0.1) mL prior to lyophilisation 
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(i.e., CM) to a volume of (7.9 ± 0.3) mL, (11.8 ± 0.8) mL, (15.0 ± 0.4) mL and (34.0 ± 4.5) mL 
when lyophilised from 15%, 10%, 5% and 1% (w/v) mannitol respectively.  
CM showed a good flow character (CI: 16.5% ± 0.8 %) whereas LMs demonstrated 
relatively poorer flow behaviours, characterized as fair (LM–15%), poor (LM–10% and LM–5%) 
and very poor (LM–1%) (Table 1). Plotting CI against mannitol concentration (Cman) indicated 
that the flowability of LM powders improved as mannitol concentration increased (Table 1). This 
is because the effect of gravity will be lower for mannitol particles lyophilised from lower 
concentrations owing to their lower density (Table 1). 
3.2. Particle size and shape distributions 
The size distributions of LM particles were strong functions of mannitol concentration 
(Table 2). The linear relationship (r2 = 0.931) (Figure not shown) established between the median 
diameter (d50%) of LM and Cman indicated that the size of LM particles increased in response to 
decreasing mannitol concentration (Table 2), which is further confirmed by SEM images (Figure 
1, SM–2). The variations in particle size distributions could be because the size of ice crystals is 
related to mannitol concentration. During the freezing, phase separation between water and 
mannitol, ice crystal growth, and solute cryo-concentration occur (Hottot et al., 2004). The 
growing ice crystals exclude mannitol molecules from its freezing front to the boundaries between 
neighbouring ice crystals. In the consequent drying process ice crystal sublimation and desorption 
of the bound water take place. The ice crystal growth depends on the adsorption/desorption 
balance of mannitol at the ice crystal surface (i.e., the adsorption and desorption of mannitol at the 
ice surface are in dynamic equilibrium). The effectiveness of a mannitol in inhibiting crystal 
growth depends on the extent of ice crystals’ surface that is covered by mannitol. Therefore, high 
mannitol concentration leads to small crystals, whereas low mannitol concentration leads to large 
ones. The span values of 0.9 and 1.1 obtained for CM and LM–1% respectively (Table 2) 
indicated their narrow size distributions. The span of LM powders was inversely proportional to 
Cman (Table 2), indicating that the decrease in mannitol concentration linearly correlated with an 
increase in the size-homogeneity of LM particles, as further substantiated by SEM observations 
(Figure 1). This might be explained as a higher concentration of mannitol could induce more 
heterogeneous nucleation and less balanced speed of growth during particle forming, leading to 
higher polydispersity in particle size distribution. Good size-homogeneity (i.e. small span) of a 
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pharmaceutical formulation is usually desirable because it will recount directly to dose 
uniformity. 
CM showed non-porous particles (Figure 1a) and hence particle true density is similar to 
particle density. LMs revealed fractured particles with wrinkled (corrugated) surfaces, producing 
open (rather than packed) particle structures (Figures 1b to e, SM–2). Such morphology increases 
the geometric interlocking among LM particles, further explaining their poorer flow properties in 
comparison to CM (Table 1). Microstructural observations with SEM supported the alternations in 
structural properties as a function of mannitol concentration. Mannitol particles lyophilised from 
concentrations ≤5% (w/v) showed macroporous surface texture characteristics composed of a 
microstructured network of particles with visible large pores and cavities (Figures 1e and d, SM–
2). This is because lyophilisation process allows the ice to sublime, leaving voids within the 
structure without major shrinkage. Therefore, large pores were less evident within mannitol 
particles lyophilised from concentrations above 5% (w/v), although a hollow structure was 
observed (Figures 1b and c, SM–2). These remarkable morphological differences between the two 
groups of LM products (i.e. LM–1% and LM–5% vs. LM–10% and LM–15%) could be due a 
variation in the mechanism of crystal nucleation and propagation. The amount of pores created 
during freeze-drying is related to the water (i.e. ice) uptake process. A relatively higher degree of 
water (ice) uptake is expected during lyophilisation of solutions with lower concentrations and 
therefore the porosity of the lyophilised product becomes higher. Such porous structure observed 
for LM particles could explain their low true density (making them permeable for helium) and 
low bulk density in comparison to non-porous CM particles (Table 1).  
3.3. Electrostatic charging 
CM and mannitols lyophilised from concentrations above 5% (w/v) showed considerably 
higher levels of netcharge (from 2.2 to 4.8 nC/g) in comparison to mannitols lyophilised from 
concentrations ≤5% (w/v) (≤0.2 nC/g) (Figure 2a). The level netcharge of LM decreased with 
decreasing mannitol concentration (Figure 2a). A clear trend of decreased netcharge with 
increasing the median diameter of LM was established (Figure 2b). This could be attributed to the 
increase in the overall surface area available for charge-transfer in the case of smaller LM 
particles due to higher particle-wall contacts, greater particle number density, and higher surface 
area (Kaialy, 2016). High levels of electrostatic charging of pharmaceuticals intended for direct 
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compression is considered as a nuisance because it leads to their adherence to the punches, dies 
and feeding hopper, affecting tablet weight and hence drug content uniformity. 
In contrast to CM, which showed a positive unipolar charging, all LMs showed 
remarkable bipolar charging behaviours (Figure 2a). For example, although the netcharge results 
showed that LM–1% carried almost no charge (0.1 nC/g), this sample recorded levels of 3.1 nC/g 
and −2.7 nC/g for P–CMR and N–CMR respectively (Figure 2a). This signifies that the 
measurement of the netcharge-to-mass ratio of a powder (using e.g. the Faraday pail method), 
where the process cause bipolar charging is not an accurate indicator for correlating the true 
charge-to-mass ratio. 
3.4. Breakability  
The median diameter (d50%) of LM particles decreased considerably with increasing the 
sonication time applied during measurements (Figure 3). This suggested that LM particles were 
fragile and suggestible to breakage with extended ultrasound application. This however does not 
offer information on the mechanism by which this reduction in particle size occurs. Therefore, the 
particle size of LM particles was determined at several time intervals at the end of the sonication 
process (200 s). The size of the sonicated LM particles did not return to its original size (data not 
shown). This suggested that the decrease in particle size upon sonication is attributable to the 
fracturing of brittle individual LM particles. For each mannitol product, the particle size profile 
reached a plateau at a particular sonication time, after which relatively ‘stable’ (P >0.05) size 
descriptors were obtained (Figure 3). From Figure 3, it can be seen that LM particles produced 
steeper decreases in sizes as a function of the increase in sonication time as compared to CM. Due 
to their increased angularity (Figure 1, SM–2), LM particles could have increased damage caused 
because of stress (Sadrekarimi and Olson, 2010). Therefore, in comparison to CM, LMs 
demonstrated considerably higher relative degrees of breakage (RDB), with the RDB increasing 
with decreasing mannitol concentration (Figure 3). This could be ascribed to the increased 
brittleness for mannitols lyophilised from lower concentrations in comparison to mannitols 
lyophilised from higher concentrations due to their relatively more porous structure and larger 
size (Table 1; Figure 1).  
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3.5. Solid-state 
LM samples produced parallel DSC traces with endothermic transitions ranging from 
(168.2 ± 0.3) ºC to (169.7 ± 1.2) ºC (mean ± SD, P >0.05) (Figure 4), corresponding to the 
melting point of the two orthorhombic polymorphs, i.e., α− or β−mannitol (Burger et al., 2000). 
The presence of the diagnostic FT−IR bands of both α− (1194 cm-1, 1370 cm-1 and 1388 cm-1) and 
β– (929 cm-1 and 959 cm-1) mannitol (Burger et al., 2000) in the FT–IR spectra of all LMs 
confirmed that they all contained both α and β forms (Figure 5). Mannitols lyophilised from 
concentrations ≤5% (w/v) exhibited an additional minor DSC endotherm with melting peaks 
ranging from (150.1 ± 0.1) ºC to (152.5 ± 4.2) ºC (mean ± SD, P >0.05), which is symptomatic to 
the presence of the monoclinic δ–mannitol (Burger et al., 2000; Kaialy et al., 2015). Such 
transition however was not observed in the DSC trace LM–10% and it was trivial for LM–15% 
(Figure 4). This was in accordance with FT−IR analysis, in which the δ–mannitol characteristic 
band (967 cm-1) was only visible in LM–1% and LM–5% (Figure 5). LMs demonstrated lower 
calorimetric melting enthalpies (from 259.1 J/g ± 3.8 J/g to 282.4 J/g ± 0.8 J/g) than CM (315.3 
J/g ± 6.1 J/g) (Figure 4). Comparing LMs only showed that the melting enthalpy of mannitol 
decreased (linearly, r2 = 0.9521, Figure not shown) with decreasing the concentration of mannitol 
(Figure 4). In addition, in comparison to CM, LM–1% exhibited broader FT−IR bands in the 
fingerprint region from 1200 cm-1 to 1500 cm-1 (Figure 5). Accordingly, both DSC and FT−IR 
analyses suggested that freeze-drying produced some defects in the structural lattice of mannitol, 
particularly in the case of low mannitol concentrations. The residual moisture measured for the 
mannitol lyophilisates was insignificant (0.2% ± 0.1%, w/w) which is ideal for storage stability 
(Barresi et al., 2009; Tang and Pikal, 2004). This agrees with DSC analysis that showed no 
endothermic transitions below 100 ºC for all mannitols (Figure 4), confirming the absence of 
detectable surface (free) water (which would have produced an endotherm at ~ 100 °C) or 
metastable monoclinic mannitol hemihydrate (which would have produced an endotherm at ~ 80 
°C (Liao et al., 2007)).  
PXRD analyses verified that all LMs contained mixtures of α–, β– and δ–mannitol in 
different quantities (Figure 6a). Mannitols lyophilised from concentrations above 5% (w/v) were 
shown by PXRD to have less amounts of δ–mannitol than mannitols lyophilised from 
concentrations ≤5% (w/v) (Figure 6a). It was clear that such low amounts of δ–mannitol were not 
detected by either DSC (because the melting point of δ–mannitol is close to the melting point of 
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α– and β–mannitol (Takada et al., 2009)) or FT−IR (probably because FT−IR analysis is limited 
to detecting a thin layer of only 1 μm). Plotting % δ–mannitol content assessed by PXRD against 
δ–mannitol transition enthalpy assessed by DSC resulted in a direct linear relationship (r2 = 
0.9903) (Figure 6b) indicating that the two techniques were in concurrence. Additionally, the 
order of % crystalline fraction analysis assessed using PXRD corresponded to % crystalline 
fraction analysis assessed using DSC (Figure 6c), both confirming that LMs have lower relative 
degrees of crystallinities (RDCs) in comparison to CM. Yet, the slight variations in the absolute % 
crystallinity data between DSC and PXRD could be attributed to the pronounced differences 
between DSC and PXRD techniques in terms of sample geometry, sample size, temperature 
program, etc. The RDC of LM decreased as the concentration of mannitol decreased (Figure 6c). 
This could be because an increase in the mannitol concentration enhances the crystallization 
behavior of LM (Kim et al., 1998). The reduced RDC of mannitols lyophilised from lower 
concentrations, in comparison to mannitols lyophilised from higher concentrations, could explain 
their lower true densities due to increased mobility (Kikuchi et al., 2011).  
3.6. Mechanical properties 
The compaction pressure played a significant role on the mechanical strength of LM 
tablets (Figure 7a). In general, the tensile strength (TS) of all tablets showed a decreasing trend 
with increasing the compression pressure (Figure 7a). It is also clear from Figure 7a that the TS of 
LM tablets are increased with decreasing mannitol concentration. This indicates stronger 
interparticle bonding between LM particles lyophilised from lower concentrations in comparison 
to LM particles lyophilised from higher concentrations, attributable to their different structural 
characteristics. It has been shown that δ–mannitol achieve superior tabletting performance as 
compared to β–mannitol (Yoshinari, 2003). Therefore, the presence of δ–mannitol in LMs (Figure 
6) could be one of the reasons for the improvement in the mechanical properties of LM tablets in 
comparison to CM tablets. However, although all LMs contained a portion of δ–mannitol, 
mannitols lyophilised from 15% (w/v) concentration did not show improved compactibility in 
comparison to CM (β–mannitol) (Figure 7a). This indicates that there are other factors in play. 
The more porous structure of mannitols lyophilised from lower concentrations (Table 1; Figure 1) 
contribute to their improved tabletability in comparison to mannitols lyophilised from higher 
concentrations. This is because the increase in powder bed porosity allows particle–particle 
interactions of greater extent during the subsequent stage of compression, resulting in higher 
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tabletability (Westermarck et al., 1998). Additionally, the lower relative degrees of crystallinity of 
mannitols lyophilised from lower concentrations in comparison to mannitols lyophilised from 
higher concentrations (Figure 6c) could be another reason for the higher tensile strengths for 
tablets made from mannitols lyophilised from lower concentrations. Moreover, the higher 
breakability of mannitols lyophilised from lower concentrations (in comparison to mannitols 
lyophilised from higher concentrations) (Figure 3) result in larger relative volume changes during 
the early stage of compression due to their fragmentation, producing tablets with higher 
tabletability. Plotting the TS of LM tablets against the RDC and RDB confirmed that mannitols 
with lower relative degrees of crystallinity (Figure 7b) and higher relative degrees of breakage 
(Figure 7c) generated tablets with better mechanical properties. 
3.7. Dissolution studies 
The dissolution rate of indomethacin tablets was enhanced when formulated with LM (in 
the form of a physical mix) (Figure 8). Such enhancement could be attributed to the betterment of 
indomethacin wettability due to the presence of relatively less crystalline (Figure 6) and highly 
porous (Table 1, Figure 1, SM–2) LM, which provides high surface area available for drug 
dissolution and a potentially increased abundance of polar groups. Regression analysis (Figures 
not shown) revealed that the DE (r2 = 0.9793) and MDR (r2 = 0.8994) have linearly increased, 
whereas MDT has linearly decreased (r2 = 0.9395), with decreasing the concentration of mannitol 
(Table 3). This could be attributed to the increased porosity (Table 1, Figure 1, SM–2) and 
decreased crystallinity (Figure 6) for mannitols lyophilised from lower concentrations in 
comparison to mannitols lyophilised from higher concentrations. The low Van der Waals forces 
between drug and LM particles (due to the high porosity of LM) could increase the effective 
surface area for dissolution resulting in an enhanced drug dissolution rate. 
Two groups of dissolution profiles could be observed for the LM–indomethacin 
formulations. Mannitols lyophilised from concentrations ≤5% (w/v) generated noticeably better 
dissolution rates of indomethacin than mannitols lyophilised from concentrations above 5% (w/v) 
(Figure 8). Mannitols lyophilised from concentrations ≤ 5% (w/v) showed a lack of significant 
difference (P >0.05) between the amounts of indomethacin dissolved after 4 min (Q4min), 10 min 
(Q10min), 30 min (Q30min) and 50 min (Q50min) (Table 3). Similarly, mannitols lyophilised from 
concentrations above 5% (w/v) produced similar (P >0.05) amounts of indomethacin dissolved 
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after 4 min (Q4min) and 10 min (Q10min) (Table 3). Such results could be related to the presence of 
two populations of morphologies of LM. Macroporous structures were observed in the case of 
LM–1% and LM–5% (Figures 1 and d) but not in the case of LM–10% and LM–15% (Figures 1c 
and b, SM−3). LM–1% produced the fastest dissolution profile of indomethacin with a complete 
dissolution after 80 min, whereas CM produced the slowest pattern of dissolution of indomethacin 
with only 33% of indomethacin being dissolved at the same time (Figure 8). In comparison to 
CM, LM–1% produced a 3.5 fold increase in the dissolution efficiency (DE: 25.1% ± 3.3% versus 
87.5% ± 0.4%) and a 4.7 fold increase in the mean dissolution rate (MDR: 0.27 min-1 ± 0.06 min-1 
versus 1.25 min-1 ± 0.07 min-1) of indomethacin (Table 3). 
Further studies could be performed to establish the influence of mannitol concentration on 
the physicochemical, mechanical and pharmaceutical properties of LM at varying lyophilisation 
protocols (e.g., different controlled cooling rates) and formulated with a wider range of drugs 
intend for both oral and pulmonary drug delivery. It would also be of interest to evaluate the 
effects of annealing conditions on the physicochemical (e.g. pore size) and mechanical properties 
of lyophilised mannitol products that showed a reduced relative degree of crystallinity (i.e., LM-
1%). 
 
4. Summary and conclusions 
The micro- and macro-structural changes of mannitol products lyophilised from solutions 
having different concentrations can be predicted. By decreasing mannitol concentration, the 
density, flowability and crystallinity of lyophilised mannitol were decreased, whereas the porosity 
and breakability (fragility) of lyophilised mannitol were increased. Clear trends of improved 
mechanical properties and enhanced dissolution rates were established with decreasing the 
concentration of mannitol solution subjected to freeze-drying. The formulators could therefore 
optimize the mechanical and dissolution properties of LM tablets via the careful selection of 
mannitol concentration prior to freeze-drying. 
This work recommends the use of mannitol lyophilised from 1% (w/v) mannitol for the 
preparation of directly compressible preparation with excellent mechanical and rapid dissolution 
properties. Mannitol particles lyophilised from the lowest concentration (1%, w/v) were ultra-
23 
 
fluffy (bulk density of only 0.03 g/cm3), porous, flake-shaped, and produced the best tablets with 
×9.1 fold increase in tablet tensile strength (5.04 MPa versus 0.56 MPa) and ×3.5 fold increase of 
dissolution efficiency (87.5% versus 25.1%) of indomethacin in comparison to commercial 
mannitol. Further optimisation of the utilization of lyophilisation in the design of mannitol 
particles with desired pharmaceutical properties should be considered. 
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Figure 1. Representative scanning electron microscope (SEM) images commercial mannitol (CM) (a) and mannitol 
lyophilised from a series of mannitol solutions with different concentrations, i.e., 1% (LM–1%) (b), 5% (LM–5%) (c), 
10% (LM–10%) (d), and 15% (LM–15%) w/v (e). 
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Figure 2. Positive charge-to-mass ratio (P–CMR), negative charge-to-mass ratio (N–CMR) and net charge-to-mass 
ratio (Net–CMR) (mean ± SD, n = 6) (a); and net–CMR in relation to median diameter (d50%) (b) of commercial 
mannitol (CM) and mannitol lyophilised from a series of mannitol solutions with different concentrations, i.e., 15% 
(LM–15%), 10% (LM–10%), 5% (LM–5%) and 1% w/v (LM–1%). 
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Figure 3. Median diameter (d50%) in relation to sonication time applied during wet-dispersion and relative degree of 
breakage (RDB) of (●) commercial mannitol (CM) and mannitol lyophilised from a series of mannitol solutions with 
different concentrations, i.e., 15% (▲, LM–15%), 10% (◊, LM–10%), 5% (○, LM–5%) and 1% w/v (■, LM–1%). 
 
 
 
32 
 
 
Figure 4. Differential scanning calorimetry (DSC) traces and melting enthalpies (mean ± SD, n = 4) of commercial 
mannitol (CM) and mannitol lyophilised from a series of mannitol solutions with different concentrations, i.e., 15% 
(LM–15%), 10% (LM–10%), 5% (LM–5%) and 1% w/v (LM–1%). 
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Figure 5. Fourier transform infrared spectroscopy (FT–IR) spectra of commercial mannitol (CM) (a) and mannitol lyophilised from a series of mannitol 
solutions with different concentrations, i.e., 15% (LM–15%) (b), 10% (LM–10%) (c), 5% (LM–5%) (d) and 1% w/v (LM–1%) (e) (%T: % transmittance). 
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Figure 6. Powder X–ray diffraction (PXRD) patterns and % crystal form (mean ± SD, n = 4) (a); % δ–mannitol content estimated by PXRD relative to δ–mannitol transition enthalpy 
measured by DSC (b); and % relative degree of crystallinity estimated by PXRD (RDCPXRD) relative to % relative degree of crystallinity estimated by DSC (RDCDSC) (c) of commercial 
mannitol (CM) and mannitol lyophilised from a series of mannitol solutions with different concentrations, i.e., 15% (LM–15%), 10% (LM–10%), 5% (LM–5%) and 1% w/v (LM–1%). 
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Figure 7. Tabletability profiles (mean ± SD, n = 5) of commercial mannitol (CM) and mannitol lyophilised from a 
series of mannitol solutions with different concentrations, i.e., 15% (LM–15%), 10% (LM–10%), 5% (LM–5%) and 1% 
w/v (LM–1%) (a); tensile strength (TS) of LM tablets compressed at different pressures (173 MPa to 1040 MPa) in 
relation to relative degree of crystallinity (RDC) (b) and relative degree of breakage (RDB) (c). 
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Figure 8. Dissolution profiles (mean ± SD, n = 3) for indomethacin tablets formulated with (●) commercial mannitol 
(CM) or mannitol lyophilised from a series of mannitol solutions with different concentrations, i.e., (■) 15% (LM–
15%), (♦) 10% (LM–10%), (▲) 5% (LM–5%) and (○) 1% w/v (LM–1%).  
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Table 1. True density (Dtrue, mean ± SD, n = 9), bulk density (Db), tap density (Dt), porosity, compactibility (1/a) (Eq. 3), cohesivity (1/b) (Eq. 3), and Carr’s 
index (CI) (mean ± SD, n = 5) of commercial mannitol (CM) and mannitol lyophilised from a series of mannitol solutions with different concentrations, 
i.e., 15% (LM–15%), 10% (LM–10%), 5% (LM–5%) and 1% w/v (LM–1%). 
Mannitol product Dtrue (g/cm3) Db (g/cm3) Dt (g/cm3) Porosity (%) 1/a 1/b CI (%) Flow character 
CM 1.50 ± 0.02 0.45 ± 0.00 0.64 ± 0.04 65.0 ± 0.5 3.35 ± 0.45 3.58± 2.40 16.5 ± 0.8 Good 
LM–15% 1.45 ± 0.02 0.11 ± 0.00 0.21 ± 0.01 91.1 ± 1.2 2.06 ± 0.03 9.74 ± 4.66 22.4 ± 2.3 Fair 
LM–10% 1.39 ± 0.01 0.08 ± 0.00 0.15 ± 0.00 93.9 ± 0.8 2.14 ± 0.02 14.70 ± 4.43 28.7 ± 1.6 Poor 
LM–5% 1.38 ± 0.04 0.05 ± 0.00 0.13 ± 0.02 95.7 ± 0.1 1.62 ± 0.20 15.28 ± 1.81 29.4 ± 1.1 Poor 
LM–1% 1.22 ± 0.06 0.02 ± 0.00 0.06 ± 0.00 97.4 ± 0.4 1.49 ± 0.03 16.16 ± 1.71 37.1 ± 1.7 Very poor 
 
Table 2. Particle size distribution (i.e. particle size at 10% (d10%), 50% (d50%, median diameter) and 90% (d90%) volume distribution and span) of commercial 
mannitol (CM) and mannitol lyophilised from a series of mannitol solutions with different concentrations, i.e., 15% (LM–15%), 10% (LM–10%), 5% (LM–
5%) and 1% w/v (LM–1%).  
Mannitol product d10% (µm) d50% (µm) d90% (µm) Span 
CM 61.6 ± 2.0 110.1 ± 3.0 177.6 ± 5.7 0.9 ± 0.1 
LM–15% 8.9 ± 3.3 72.7 ± 11.2 196.5 ± 66.4 1.7 ± 0.0 
LM–10% 18.1 ± 2.8 101.3 ± 2.2 259.7 ± 48.4 1.5 ± 0.1 
LM–5% 23.0 ± 3.2 118.0 ± 4.8 269.6 ± 14.8 1.2 ± 0.0 
LM–1% 48.6 ± 5.1 168.3 ± 5.5 288.1 ± 15.1 1.1 ± 0.0 
 
Table 3. Dissolution efficiency (DE120min), mean dissolution time (MDT), mean dissolution rate (MDR) of indomethacin, and amount of indomethacin (%) 
dissolved after 4 min (Q4min), 10 min (Q10min), 30 min (Q30min) and 50 min (Q50min) (mean ± SD, n = 3) from tablets containing commercial mannitol (CM) or 
mannitol lyophilised from a series of mannitol solutions with different concentrations, i.e., 15% (LM–15%), 10% (LM–10%), 5% (LM–5%) and 1% w/v 
(LM–1%). 
Mannitol product DE120min (%) MDT (min) MDR (min-1) Q4min (min) Q10min (min) Q30min (min) Q50min (min) 
CM 25.1 ± 6.3 54.1 ± 2.1 0.27 ± 0.07 4.0 ± 1.6 4.6 ± 1.2 14.4 ± 3.0 22.3 ± 5.3 
LM–15% 62.7 ± 6.5 40.7 ± 6.9 0.70 ± 0.07 4.0 ± 1.0 10.9 ± 1.4 39.5 ± 9.3 66.6 ± 13.9 
LM–10% 70.4 ± 1.3 35.5 ± 1.6 0.76 ± 0.07 4.7 ± 0.7 13.6 ± 1.4 51.5 ± 4.6 76.9 ± 2.5 
LM–5% 83.4 ± 1.1 18.2 ± 0.3 1.19 ± 0.05 19.2 ± 5.0 55.7 ± 0.9 79.2 ± 1.8 86.5 ± 3.6 
LM–1% 87.5 ± 0.4 15.0 ± 0.5 1.25 ± 0.07 17.1 ± 0.3 58.6 ± 5.1 87.8 ± 0.7 94.2 ± 0.9 
 
